**Think Outside the Eye. Treat Skin and Eyelid Inflammation.**

Do your patients suffer from dry, itchy, red or burning eyes? This may be caused by skin and eyelid inflammation that affects their eye condition.

Lumenis invites you to think outside the eye and to offer your patients a solution to their skin related problems.

---

"Although rosacea is predominantly a skin condition, it often leads to eyelid and ocular surface inflammation, which can then trigger meibomian gland dysfunction (MGD), the major cause of dry eye disease (DED)" (Ronald N. Gaster, MD)

---

**System Specifications**

- **Universal IPL**
  - Wavelength: 500-1200 nm
  - Pulse Duration: 5-200 ms
  - Pulse Energy: 1-150 J/cm²
  - Pulse Characteristic: Multiple Sequential Pulsing
  - Repetition Rate: 1-25 Hz
  - Spot Size: 35 x 15 mm²; 15 x 8 mm²
  - Cooling: Continuous contact cooling

- **Multi-Spot™ Nd:YAG**
  - Wavelength: 1064 nm
  - Fluence: 10-600 J/cm²
  - Pulse Duration: 2-20 ms
  - Pulse Delay: 5-100 ms
  - Pulse Characteristic: Multiple Sequential Pulsing
  - Repetition Rate: 1-10 Hz
  - Spot Size: 6 mm; 2 x 4 mm²; 9 mm x 1.5 mm
  - Cooling: Continuous contact cooling

- **Q-Switched Nd:YAG**
  - Wavelength: 1064 nm
  - Pulse Duration: 6-8 nsec
  - Pulse Characteristic: Top-Hat
  - Repetition Rate: 0.5-5.0 Hz
  - Spot Size: 2; 2.5; 3.5; 4; 5; 6 and 8 mm

- **ResurFX™**
  - Wavelength: 1565 nm
  - Pulse Energy: 10-70 mJ per micro-beam
  - Pulse Characteristic: CoolScan™
  - Pattern Shapes: Line, square, rectangle, circle, donut, hexagon
  - Beam Density: Up to 500 micro-beams/cm²
  - Repetition Rate: 0.5-2 Hz
  - Tip: Sapphire; Precision Spot Size: Up to 18 mm
  - Cooling: Continuous contact cooling

---

Courtesy of Dr. Rob Noecker, MD

---

Skin and eyelid inflammation affects millions of Americans every year. Over 85% of skin and eyelid inflammation patients also suffer from inflammatory ocular conditions, such as Meibomian Gland Dysfunction (MGD), blepharitis, eyelid inflammation and eyelid telangiectasia.

Lumenis invites you to think outside the eye and offer your patients a solution to their skin related problems with M22™. M22™ combines Intense Pulsed Light (IPL) with unique Optimal Pulse Technology (OPT™), and FDA cleared for 20 different skin indications, including rosacea and other skin inflammatory conditions.

Lumenis M22™ IPL with OPT™

Optimal Efficacy and Safety

When using IPL on your patients facial skin, especially in vicinity to the eyelids, efficacy and safety are essential. OPT™ is the most advanced IPL technology, developed by Lumenis, and is unique to Lumenis M22™.

OPT™ allows:

- Reliability
  The energy you choose is the energy you get

- Safety
  Equal energy distribution over the entire pulse, no energy peaks that may lead to unintended effects and no energy drops that result in misdetection

- Efficacy
  Reproducible results

IPL: An Excellent Technology for Treating Skin and Eyelid Inflammation

Inflammatory skin diseases are characterized by the formation of vascular abnormalities, which release inflammatory agents. When occurring in proximity to the eyes, these mediators propagate via the orbital vasculature to the eyelids, resulting in inflammation of the eyelids and triggering ocular complications.

IPL, an excellent technology for treating vascular skin lesions, is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombosis. A major source of inflammation threatening the eyelids is then removed.

Enhanced Physician and Patient Comfort

M22™-IPL with OPT™ features unique features for enhanced physician and patient comfort:

- Lumenis unique presets allow the physician to optimally treat numerous skin indications
- ExtendIPL™ adapted to the skin type and condition for optimized results
  All suitable for one handpiece
- SapphireCool™ light guide, a chiller tip, for maximal patient comfort

Enhanced Physician and Patient Comfort

IPL is an excellent technology for treating vascular skin lesions, IPL is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombosis. A major source of inflammation threatening the eyelids is then removed.

Baseline

4 Months Post Treatment

"Many of the patients who received IPL with OPT ™ treatment (for Rosacea) reported that symptoms such as dry, itchy eyes improved and decreased their need for artificial tears.

(ROLANDO TOYOS, MD)


Inflammatory skin diseases are characterized by the formation of vascular abnormalities, which release inflammatory agents. When occurring in proximity to the eyes, these mediators propagate via the orbital vasculature to the eyelids, often resulting in inflammation of the eyelids and triggering ocular complications.

IPL is an excellent technology for treating vascular skin lesions. IPL is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombosis. A major source of inflammation threatening the eyelids is then removed.

IPL is an excellent technology for treating vascular skin lesions. IPL is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombosis. A major source of inflammation threatening the eyelids is then removed.

Looking to Expand Your Practice?

The M22™ is a modular system, allowing your practice to expand to aesthetic treatments, by using your IPL handpiece, as well as adding new modules to your existing M22™, at any time you want.

M22™ additional modules:

- ResurfX™: Fractional non-ablative skin resurfacing.

All applications have presets, allowing you to safely and professionally expand your practice.

Universal Handpiece with
SapphireCool™ light guides,
for maximal patient comfort.

“DED (Dry Eye Disease) and aesthetics are two big opportunities for expanding an ophthalmology practice. A single technology, intense pulsed light, could offer solutions to both” 4 (Steven J. Dell, MD)

"DED (Dry Eye Disease) and aesthetics are two big opportunities for expanding an ophthalmology practice. A single technology, intense pulsed light, could offer solutions to both" 4 (Steven J. Dell, MD)


M22 is FDA cleared only for skin indications, and is under clinical trials for M22/DDE.